Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Platelet and serum BDNF level and response to rTMS treatment ; A nested prospective cohort study in Croatia (CROSBI ID 685453)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Ruljančić, Nedjeljka ; Filipčić, Igor ; Šimunović Filipčić, Ivona ; Gajšak, Tomislav ; Milovac, Željko ; Sučić, Strahimir ; Zečević Penić, Sandra ; Bajić, Žarko Platelet and serum BDNF level and response to rTMS treatment ; A nested prospective cohort study in Croatia // Clinical chemistry and laboratory medicine. 2018. str. eA340-eA340 doi: 10.1515/cclm-2018-1038.

Podaci o odgovornosti

Ruljančić, Nedjeljka ; Filipčić, Igor ; Šimunović Filipčić, Ivona ; Gajšak, Tomislav ; Milovac, Željko ; Sučić, Strahimir ; Zečević Penić, Sandra ; Bajić, Žarko

engleski

Platelet and serum BDNF level and response to rTMS treatment ; A nested prospective cohort study in Croatia

Purpose: Transcranial magnetic stimulation (TMS) is indirect and non-invasive methods used to induce an electric current in the motor cortex generating a magnetic field that passes through the scalp. Several research were shown higher serum or plasma BDNF level after rTMS treatment but in some there were no connection between serum or plasma BDNF and rTMS treatment in depressed patients. The objective of this study was to examine whether the outcome of rTMS treatment of MDD (major depressive disorders) can be predicted by platelet or serum BDNF concentration levels. Materials and Methods: This prospective cohort study was nested within the randomized controlled trial conducted at Psychiatric Hospital Sveti Ivan, Zagreb, Croatia during 2017, on the sample of 15 patients, median (IQR) age of 56 (46-63), male 10/female 5 (Table 1.). Outcome was the change in Hamilton Depression Scale (HAM-D17) after four weeks treatment with rTMS. The serum and platelet BDNF concentration has been determined by enzyme- immunoassay method. The content of platelet BDNF is referred to ng/ 109 platelets. The main analysis was done by robust regression. Results: After four weeks treatment with rTMS, platelet and serum BDNF concentrations were not significantly changed (Table 2). Baseline concentration of platelet BDNF was univariately significantly associated with the absolute change of HAM-D17 result adjusted for the baseline HAM-D17 values (R2=0.32 ; p=0.045). This association strengthened after the adjustments for age and sex (b=0.51, β=0.95, t=3.89, p=0.006). Conclusions: Platelet BDNF baseline concentration is a promising biomarker of TMS efficacy in treatment of MDD.

Platelet BDNF ; Transcranical magnetic stimulation ; Major depressive disorder

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

eA340-eA340.

2018.

nije evidentirano

objavljeno

10.1515/cclm-2018-1038.

Podaci o matičnoj publikaciji

Clinical chemistry and laboratory medicine

1437-4331

Podaci o skupu

5th EFLM-UEMS European Joint Congress in Laboratory Medicine

poster

10.10.2018-13.10.2018

Antalya, Turska

Povezanost rada

Temeljne medicinske znanosti

Poveznice